Angiotensin II type 1 receptor blockade after cardiac transplantation reduced the incidence and severity of transplant vasculopathy in an animal-based study.
Richter
M H C
MH
Experimental Heart Transplant Group, Frankfurt, Germany.
Richter
H
H
Barten
M
M
Schramm
D
D
Gummert
J
J
Mohr
F W
FW
Skupin
M
M
Olbrich
H G
HG
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D003327:Coronary Disease / Q000517:prevention & control*; D004656:Enalapril / Q000494:pharmacology; D016027:Heart Transplantation / Q000473:pathology / Q000502:physiology*; D019808:Losartan / Q000494:pharmacology*; D023421:Models, Animal; D011183:Postoperative Complications / Q000517:prevention & control; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D044140:Receptor, Angiotensin, Type 1; D014652:Vascular Diseases / Q000517:prevention & control*
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D044140:Receptor, Angiotensin, Type 1; D004656:Enalapril; D019808:Losartan